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Abstract 
Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on 
patients and their families. The Cancer Genome Atlas (TCGA) and similar projects have provided a 
comprehensive understanding of the somatic alterations and molecular subtypes of glioma at 
diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease 
progression. We review the current knowledge on the genomic and epigenetic abnormalities in 
primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the 
need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma 
Longitudinal AnalySiS Consortium (GLASS) aims to systemically catalog the longitudinal changes in 
gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a 
lethal phenotype, with the potential to reveal targetable vulnerabilities, and ultimately, improved 
outcomes for a patient population in need. 
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1. Introduction 
Diffuse gliomas are the most frequent primary brain tumors in adults
1
. Almost all gliomas 
relapse despite intensive treatment with surgery, radiation, and chemotherapy. The most common and 
most aggressive gliomas, glioblastoma (GBM), are IDH-wildtype and classified as 2016 World Health 
Organization (WHO) grade IV. They are characterized by a median overall survival that has remained 
static at around 15 months for decades, even in selected clinical trial populations
2-4
. Patients with 
lower-grade (WHO grades II) IDH-mutated gliomas have a more favorable prognosis, but these 
tumors progress and recur as higher grades (III and IV) and become resistant to therapy
1
. The standard 
of care for diffuse gliomas is maximal safe resection, followed by chemoradiation (Figure 1)
5
. Patients 
are then monitored for disease progression by imaging at regular intervals following surgery. 
Evaluation of disease progression is commonly guided by specific imaging criteria (e.g., Response 
Assessment in Neuro-Oncology [RANO])
6
, which rely on visual evaluation of contrast enhancement 
and the non-enhancing hyperintense area on T2-weighted imaging. Radiologic features sometimes do 
not distinguish between true tumor progression and its imaging mimicker, pseudo-progression, which 
can result in premature withdrawal from a specific treatment or the continuation of an ineffective 
therapy. 
Molecular characterization of gliomas has advanced our understanding of their genesis
7-18
 and 
has identified somatic alterations that allow their classification into subtypes with different biology 
and median survival times
19
. This wealth of information has provided a detailed molecular portrait of 
primary glioma. The Cancer Genome Atlas (TCGA), which characterized 1,100 grades II-IV gliomas 
in detail, has by design focused on untreated tumors. The next frontier in glioma genomics is to 
understand recurrent disease, as patients generally die from increasingly resistant tumor regrowth after 
therapy. Recent pilot studies of paired tumors obtained before and after therapy show that there are 
many differences between the primary neoplasm at diagnosis and the recurrent tumor
20
. Progression of 
gliomas is the result of an evolutionary process that involves iterative cycles of clonal expansion, 
genetic diversification, and clonal selection under microenvironmental pressures, including 
overcoming antitumor immune responses
21
. The presence of multiple cell populations with an array of 
different somatic mutations is at least partly responsible for the rapid induction of intrinsic resistance 
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to therapy in gliomas
22
. Adaptive epigenetic and phenotypic responses are equally important. The 
emerging understanding of this dynamic evolution of the glioma genome has major implications for 
cancer biology research and potential development of effective therapies. This can only be achieved 
through (a) profiling of sufficiently large primary/recurrent patient tumors and associated imaging to 
collect enough patients in order to capture low frequency variants or subtle therapy driving processes; 
and (b) standardization across biospecimen processing and data platforms. Here, we discuss the 
current literature on preliminary molecular longitudinal characterization of gliomas (Table 1) and 
introduce the Glioma Longitudinal AnalySiS (GLASS) Consortium, which has been initiated to 
establish a definitive portrait of the recurrence process and in doing so, discover vulnerabilities that 
render the tumor sensitive to therapeutic intervention (Figure 2). 
 
2. Molecular profiling offers new possibilities for diagnosis and therapy of gliomas 
2.1 Clinical classification of adult diffuse glioma 
Historically, the diagnosis of diffuse gliomas relied purely on microscopic evaluation
23
, but 
more recently the combination of histopathology with specific molecular characteristics of gliomas 
has proven more objective for clinical stratification
9, 11, 17-19, 24-29
. Gliomas are initially split based on 
the mutation status of the isocitra e dehydrogenase (IDH) 1 or 2 genes. Tumors with wild type alleles 
are called IDH-wildtype and 95% are glioblastomas
12
. Tumors with IDH mutations are further 
subdivided based on the presence of complete 1p/19q codeletion (IDH mutant codeleted) or TP53 
mutation and ATRX loss (IDH mutant non-codeleted)
9, 11, 17, 18, 24, 26-29
. Most WHO grade II and III 
diffuse astrocytomas and oligodendrogliomas are IDH mutant, and contain 1p/19q codeletion. 
Consensus on how this revised molecular classification should be implemented in routine clinical 
practice
25
 is outlined in the latest WHO 2016 classification of central nervous system tumors
19
. For the 
first time, this scheme provides data for diagnosis, prognostic grading, and guiding therapeutic 
decisions
30, 31
. However, this improved classification system is predicated on primary untreated 
disease, and it remains unclear how these molecular markers impact the biology and prognosis 
following diagnosis. The DNA methylation status of the MGMT gene promoter is predictive of 
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response to temozolomide therapy in primary GBM, and this status appears to be largely stable 
between primary and recurrent disease
32
. The value of re-testing MGMT status after disease 
progression is debatable and a methylated MGMT promoter continues to predict treatment response at 
this stage. 
 
2.2 Intratumoral heterogeneity in primary gliomas 
Cancer results from a single normal cell that has acquired molecular alterations providing it 
with a growth advantage. In glioma, the most frequent somatic abnormalities are thought to be 
founding events
33
. This includes somatic mutations in the IDH genes and in the promoter of the 
telomerase reverse transcriptase (TERT) gene, which is characteristic of IDH-wildtype GBM as well 
as IDH-mutant codeleted gliomas
24
. Major aneuploidy, such as 1p/19q codeletion, whole chromosome 
7 gain, and chromosome 10 loss (IDH-wildtype gliomas), are also thought to be glioma-initiating 
alterations
34-36
. The three major glioma subtypes reflect different patient age at diagnosis distributions, 
which further suggests that the three groups represent distinct gliomagenic biologies. 
Cancer cell descendants of the same cell of origin may contain a wide range of genetic and 
epigenetic states
37, 38
. This intratumoral heterogeneity confounds diagnosis, challenges the design of 
effective therapies, and is a determinant of tumor resistance
39
. Molecular heterogeneity in GBM has 
been characterized using multiple approaches. For example, fluorescent in situ hybridization analysis 
of the most commonly amplified receptor tyrosine kinases (RTK) in GBM (EGFR, PDGFRA, and 
MET) revealed a mosaic of tumor subclones marked by different RTK amplifications in 2–3% of 
GBM
40, 41
, possibly indicating cooperation between cell populations. Single-cell sequencing 
demonstrated comparable non-overlapping subclonal GBM cell populations marked by different 
EGFR truncation variants, suggesting convergent evolution of EGFR mutations
42
. Genomic profiling 
of spatially distinct tumor sectors has revealed partial overlap in the mutation content in multiple 
samples from IDH-mutant lower-grade glioma
17, 36, 43, 44
 and IDH-wildtype GBMs
34, 35, 45-47
. Somatic 
mutations/DNA copy number alterations in important glioma driver genes such as TP53 and PTEN 
have been found to be subclonal, suggesting they were acquired after tumor initiation. These 
unexpected discoveries show the many genetic routes tumor cells can take to overcome anti-
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tumorigenic barriers such as senescence and genomic instability. The possibility of extrachromosomal 
oncogene amplification adds an additional layer of complexity, allowing tumors to rapidly increase 
intratumoral heterogeneity in response to a microenvironment sparse in resources
48-53
. 
Intratumoral mutation retention rates may be correlated with the geographical distance 
between samples in the tumor
47
, and by extension, the level of heterogeneity between different lesions 
of multifocal GBM is greater than between different areas in the same GBM
47, 54, 55
. Spatial 
heterogeneity determined by genetic alterations is reflected in the epigenetic patterns of different 
tumor sections examined by combined analysis of DNA methylation and genetic abnormalities
43, 46
. 
These accumulating data suggest that intratumoral heterogeneity is encoded through a genomic–
epigenomic codependent relationship
43
, in which epigenetic changes may modulate mutational 
susceptibility in proximal cells, and specific mutations dictate aberrant epigenetic patterns
43, 56, 57
. 
Although gene expression signatures can be used to subclassify GBMs, the predominant subtype often 
varies from region to region within a given tumor
35, 46
. This relative instability may be in part due to 
the variable levels of tumor-associated non-neoplastic cells that can be found in different parts of the 
tumor
58, 59
. Single-cell RNA sequencing of GBM cells has shown that glioma cells from the same 
tumor can correspond to different glioma subtypes, often with one dominating the others
47, 59-61
. 
Single-cell transcriptomics extends previous observations of mosaic RTK amplification in a small 
subset of GBM to be a more common disease characteristic
60, 61
. Single-cell RNA sequencing further 
has shown cellular hierarchies along an axis of undifferentiated progenitors to more differentiated cell 
populations, reminiscent of the hematopoietic stem cell hierarchy. The balance shifts toward 
proliferating progenitors in IDH-wildtype glioma, reflecting the clinically more aggressive disease 
course
62, 63
. These developmental and functional hierarchies are associated with dynamic neural stem 
cell expression patterns in which stem or progenitor cells may function as units of evolutionary 
selection (Figure 2). 
 
2.3 Longitudinal DNA profiling in pre-treatment and post-treatment tumors 
One of the earliest reports on the effects of therapy on the tumor genomic landscape analyzed 
a 23-patient cohort of IDH-mutant lower-grade gliomas treated with temozolomide chemotherapy
64
. A 
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subset of the recurrent tumors acquired hundreds of new mutations that bore a characteristic signature 
of temozolomide-induced mutagenesis, suggesting that treatment pressure from an alkylating agent 
induced the growth of tumor cells with new mutations
36
. These hypermutated tumors may be sensitive 
to immune checkpoint inhibitors
22
, including programmed death-1 (PD-1) inhibitors
65
 and poly-
adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi)
66
. However, clinical trial data 
supporting these hypotheses have yet to emerge. Another study used whole-genome and multisector 
exome sequencing of 23 predominantly IDH-wildtype GBM and matched recurrent tumors
34
. This 
study showed that some GBM recurrences carried ancestral p53 driver mutations detectable in the 
primary GBM counterparts, suggesting an intrinsic resistance mechanism. Other recurrences were 
driven by branched subclonal mutations not present in the parental primary GBM. This may imply 
secondary or extrinsic resistance, reflecting treatment-induced resistance through DNA mutagenesis 
and a distinct evolutionary process (Figure 2)
34
. As in the study of IDH-mutant lower-grade gliomas, a 
subset of the disease recurrences was characterized by an accumulation of mutations in association 
with temozolomide treatment. Notably, this effect was limited to cases with MGMT promoter 
methylation. MGMT is a gene in the DNA repair pathway, and somatic mutations of other pathway 
members, such as MSH2 and MSH6, have been identified as drivers of the hypermutation process
67
. 
The spatiotemporal evolutionary trajectory in paired gliomas between initial diagnosis and relapse was 
further portrayed via integrative genomic and radiologic analyses through whole-exome sequencing 
(WES) of 38 primary and corresponding recurrent tumors
68
. Linear evolution, reminiscent of intrinsic 
resistance in which a recurrent tumor is genetically similar to the initial tumor, was predominantly 
observed in recurrent tumors that relapsed adjacent to the primary site. Branched evolution, associated 
with secondary or extrinsic resistance, was more common in recurrences at distant sites, which were 
marked by a substantial genetic divergence in their mutational profile from the initial tumor, with key 
driver alterations differing in more than 30% of cases. Geographically separated multifocal tumors 
and/or long-term recurrent tumors were seeded by distinct clones, as predicted by an evolution model 
defined as multiverse; i.e., driven by multiple subclonal cell populations
47
. In an effort to elucidate the 
diverse evolutionary dynamics by which gliomas are initiated and recur, the clonal evolution of GBM 
under therapy was assessed from an aggregated analysis of datasets generated by multiple 
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institutions
69
. Systematic review of the exome sequences from 93 patients revealed highly branched 
evolutionary patterns involving a Darwinian process of clonal replacement in which a subset of clones 
with a selective advantage during a standard treatment regimen renders the tumor susceptible to 
disease progression (Figure 2). Mathematical modeling delineated the sequential order of somatic 
mutational events that constitute GBM genome architecture, identifying somatic mutations in IDH1, 
PIK3CA, and ATRX as early events of tumor progression, whereas PTEN, NF1, and EGFR alterations 
were predicted to occur at a later stage of the evolution
47
. Similar observations have been reported 
from studies of low-grade gliomas, demonstrating that the somatic mutations in IDH1, TP53, and 
ATRX were frequently early and retained throughout tumor progression from primary to relapse
17, 44
. 
Longitudinal profiling of paired samples continues to provide deeper insights into the genomic 
background of treatment-induced hypermutagenesis. The latter has potential to increase aggressive 
clinical behavior and relevance in targeted and immunotherapy
17, 44, 70, 71
. The implications of these 
pilot data and how these insights can be integrated into clinical practice require further evaluation. 
Collectively, longitudinal genomic profiling will be essential in implementing clinical application 
toward patient-tailored treatment regimens. 
 
2.4 Transcriptional changes during glioma progression 
Unsupervised transcriptome analysis of GBM converged on four expression subtypes, referred 
to as classical, mesenchymal, neural, and proneural, which are associated with specific genomic 
abnormalities
12, 14, 15, 72
. 
Transcriptional subtypes of the relatively homogeneous IDH-mutant and IDH-mutant 1p/19q-
codeleted groups have been less emphasized in the literature, as these cases usually carry a proneural 
signature
10, 12
. While expression subtype classification is a widely used research tool, it has not been 
shown to correlate with clinical outcome, and has not been incorporated in the recent 2016 WHO CNS 
tumor classification update. Much is still unknown about how transcriptional subclasses evolve under 
therapy. A switch from proneural to mesenchymal expression has been observed upon disease 
recurrence and was proposed to be a source of treatment resistance in GBM relapse
15, 73, 74
, but the 
relevance of this phenomenon in glioma progression remains ambiguous, particularly considering (a) 
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the increased fraction of microglial/macrophage cells in mesenchymal GBM that confound subtype 
characterization
58, 59
; and (b) glioma neurospheres derived from mesenchymal GBM are frequently 
classified as proneural
74
. Deriving an expression subtype classification on the basis of glioma-intrinsic 
genes has maintained the proneural, classical, and mesenchymal classes
59
. Determining subtypes in a 
cohort of 91 IDH-wildtype GBM showed subtype switching following therapy and disease relapse in 
45% of the cohort
59
. These patterns converged with changes in the microenvironment, but also 
revealed that NF1 loss results in macrophage/microglia recruitment. The ability of genomic 
abnormalities to regulate the tumor microenvironment shows how tumors act as a system, rather than 
an aggregation of individual cells. 
 
2.5 Epigenetic changes during glioma progression 
DNA methylation profiling of gliomas has prognostic value independent of patient age and the 
pathologic grade of the tumor
9
. Evidence suggests that evolutionary selection can also act on the 
epigenome, affording cells plasticity to resist therapy
9, 43
. For example, recurrent IDH-mutant gliomas 
profiled for mutations and DNA methylation independently evolved deregulation of their cell cycle 
programs through genetic mutations or epigenetic mechanisms
43
. 
Nearly all IDH-mutant gliomas exhibit a characteristic CpG island hypermethylator phenotype 
(G-CIMP), which (i) induces silencing of key extracellular matrix and cell migration gene 
promoters
10
; (ii) mediates alteration of chromosome topography, leading to oncogene upregulation
75, 
76
; (iii) mediates histone methylation-related changes in gene expression; and (iv) may play a role in 
creating an immunosuppressed microenvironment
77
. While almost all IDH-mutant tumors are G-CIMP 
at diagnosis, a longitudinal analysis showed that 34% of cases exhibited demethylation toward G-
CIMP-intermediate or G-CIMP-low DNA methylation at recurrence
78
. Substantial epigenetic 
heterogeneity between tumor samples from the same patient collected at subsequent surgeries was also 
observed in a cohort of 112 primary mostly non-G-CIMP GBM patients
79
. Characteristic trends in 
DNA methylation between primary and relapsed GBM included a prominent demethylation of gene 
promoters related to Wnt signaling, which was associated with worse patient outcome. Moreover, 
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patients whose primary tumors harbored higher levels of DNA methylation heterogeneity showed 
longer progression-free survival and a trend toward longer overall survival
79
. 
 
2.6 Imaging and (epi)genomics 
MRI is noninvasive, with no risk of radiation exposure. Standard MRI includes precontrast 
and post-contrast T1-weighted (T1w) and T2-weighted (T2w)/T2w fluid-attenuated inversion recovery 
(T2-FLAIR) imaging assessing tumor location, size, and other features
80
. Newer techniques such as 
perfusion imaging provide a measure of tumor vascularization in terms of relative cerebral blood 
volume, which correlates with tumor grade
81, 82
. There is interest in exploring the relationships 
between MR findings such as cerebral blood volume with the biological behavior of tumors, for 
example to determine risk prior to surgery. 
In the rapidly growing field called radiogenomics
83
 quantitative imaging features can be 
linked with genomic profiles, with recent applications in high-grade glioma
83, 84
. A priority of 
radiogenomics is to identify MRI-based biomarkers for glioma subtypes such as IDH-mutant versus 
wildtype and 1p/19q codeleted versus non-codeleted. Noninvasive phenotypical assessment provides 
an early test to stratify IDH-mutant non-codeleted gliomas and may offer prognostic information 
through MRI with the potential to influence patient outcomes and determine risk prior to surgery
85
. It 
may also help in selecting personalized treatments in clinical trials
86
. A detailed global assessment of 
the spatial and longitudinal heterogeneity of gliomas is potentially feasible
87
. 
 
3. Barriers to progress 
The major obstacle for glioma patients is a lack of effective treatments, which may result from 
cell-intrinsic resistance or treatment-resistant glioma cells being favored over treatment-sensitive cells, 
augmented or attenuated by microenvironmental influences including hypoxia and stromal elements. 
That therapy has profound effects on tumor composition is reflected by the temozolomide-induced 
hypermutator phenotype
64
. As a result, the molecular characteristics of the recurrent tumor differ in 
significant ways from those found in the primary tumor
34, 36
. The TCGA and similar initiatives 
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elsewhere have established comprehensive portraits of the interpatient variability of untreated glioma 
genomes. Single-cell sequencing and barcoding experiments have demonstrated functional hierarchies 
providing important insights into characteristics of the most relevant cells to target
62, 63
. We are 
increasingly able to infer the life history of glioma
33
, from germline predispositions 
88, 89
tumor-
initiating events such as IDH1 mutation to tumor-promoting events such as RTK alterations. To 
improve the outcomes of patients with gliomas, we need to establish a thorough understanding of the 
treatment-induced molecular and genetic diversity that leads to resistance. 
A detailed understanding of the biological diversity within every tumor following clinical 
presentation and disease progression is needed if we are to successfully understand how treatment 
affects glioma progression. This is an essential step toward the integration of precision therapeutics 
into clinical decision-making, highlighting the danger in considering treatment options for patients 
with recurrent tumors solely on the basis of the molecular analysis of their treatment-naïve tumors. 
This is particularly important in the setting of clinical research, which often recruits patients with 
recurrent GBM to evaluate drugs developed on the basis of mechanistic data obtained on treatment-
naïve tumors. 
Studying the heterogeneity and spatiotemporal evolution of cancer in general, and particularly 
in brain cancer, is challenging. Many tumor samples, and therefore large-scale collaboration, are 
needed to achieve meaningful comprehensive results and to capture low frequency alterations or subtle 
therapy-driving processes. Individual research groups typically do not have the resources to use a 
multiplatform analysis of their samples, owing to cost or the availability of expertise. Published 
longitudinal datasets consist of a mixture of different modalities, ranging from only exomes
36
 or DNA 
methylation profiles
43, 79
 to a combination of exome sequencing, RNA sequencing, and DNA copy 
number profiling
34, 59
, thwarting meta-analyses based on cross-publication comparisons. The value of 
establishing a comprehensive multiplatform reference dataset quickly has been demonstrated by the 
success of TCGA, the International Cancer Genomics Consortium (ICGC), the Therapeutically 
Applicable Research to Generate Effective Treatments (TARGET) Consortium and other glioma 
projects, which have led to a fundamental reclassification of gliomas by the WHO
19
 and are highly 
cited
8, 10-12, 90, 91
. Similarly, a consortium would be the most effective approach to assemble the large 
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cohorts of primary and recurrent tumor pairs needed to identify somatic alterations enriched after 
disease progression. Systematizing and standardizing what we do and how we do it will be essential 
for change to clinical practice in neuro-oncology. This philosophy is at the core of the international 
GLASS Consortium. 
 
4. The Glioma Longitudinal AnalySiS (GLASS) Consortium 
Large-scale collaborations are needed to help us understand the impact of treatment on 
evolutionary dynamics and thereby develop novel treatments to prevent and overcome resistance to 
treatment. GLASS aims to perform comprehensive molecular profiling of matched primary and 
recurrent glioma specimens from 1,500 patients, 500 in each of the three major glioma molecular 
subtypes. At the time of writing, the consortium includes investigators from 34 academic hospitals, 
universities, and research institutes from 12 countries (see list of participants on the GLASS website, 
http://www.glass-consortium.org). By analogy with the ICGC
90
, GLASS is structured into country-
specific franchises (GLASS-NL, GLASS-AT, GLASS-AU, GLASS-Korea, etc.) led by local 
investigators who are invested in the team’s overall goal, while taking advantage of country-specific 
opportunities. This enables each GLASS branch to have unique features that allow a deeper analysis 
of subcohorts; that is, with additional imaging annotation, parallel characterization of drug response 
through xenografting of tumor samples, autopsies, a specific focus on a glioma subtype, etc., thereby 
making them competitive and enabling them to address non-overlapping aspects of the phenotypic 
diversity seen in the clinic. Country-specific branches will be coordinated to connect with the larger 
analyses, and to drive specific research topics for both. There are no explicit restrictions on publishing, 
and each group is invited to publish their substudies independently. The overall goal is to establish a 
reference dataset by pooling samples and aggregate data from all multiplatform analyses, countries, 
and substudies, and to make datasets comparable through coordinated sample and data processing 
guidelines. Country franchises are centrally connected through a number of committees, each 
overseeing different aspects of the analysis. 
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Biospecimens from gliomas are often snap-frozen or conserved as formalin-fixed, paraffin 
embedded (FFPE) samples. For genomic and transcriptomic analyses, snap-frozen material is 
preferred, while historically FFPE is the common approach to tissue preservation. Methods for 
generating sequencing data from FFPE material are increasingly improving, with 5–20% of samples 
failing quality controls. Given that samples from multiple timepoints are required for inclusion into 
GLASS, patients for whom only FFPE material is available are twice as likely to not yield sufficient 
high quality DNA. While the increased failure rate means we will have to include a higher number of 
samples, we do not see this as prohibitive and are actively pursuing the use of FFPE material. RNA 
extracted from glioma tissue is often highly degraded, resulting in higher attrition rates
92
, but high 
quality RNA sequencing data from FFPE samples has been reported
93
. For DNA methylation profiling 
of FFPE material, a recent study focusing on primary glioblastoma reported a high success rate using 
the reduced representation bisulfite sequencing assay
79
. 
While we require the availability of a matching germline sample (blood or other) for inclusion 
of DNA sequencing data into GLASS, cases without a germline match may be candidates for 
transcriptome and DNA methylation analysis. Ideally, we aim to generate DNA, RNA, and 
epigenomic sequencing data from every tumor. Single-cell analysis methods require fresh tissue from 
which individual cells can be dissociated; this may be considered in the future as the project evolves or 
as part of specific subprojects. Similarly, subsets of the GLASS cohort will be compared 
longitudinally by spatial correlation using multisector analysis (3–6 samples per tumor) to understand 
whether any differences between paired tumor samples are the result of intratumoral heterogeneity or 
longitudinal heterogeneity. Where available, these will be correlated with conventional and novel MR 
imaging to explore spatiotemporal heterogeneity noninvasively. We aim to take current radiogenomic 
approaches further, not only to establish the features of genetic characteristics at first diagnosis, but 
also in relation to molecular alterations over time and under the pressure of standard therapy. 
Comprehensive genomic sequencing is needed to identify patterns of disease evolution as well as the 
key mutations and chromosomal alterations that confer resistance to standard radiation, temozolomide, 
and novel clinical trial therapies. Sequencing paradigms and their costs are rapidly evolving, and each 
method provides different but complementary information. There is no consensus on optimal methods. 
4.1 Biospecimen acquisition and characterization platforms 
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With the accessibility of 30x coverage whole-genome sequencing (WGS) at $1,100 per biospecimen, 
the costs of WGS and WES have become comparable. The coverage of a typical WES is between 60–
100x, which enables greater sensitivity in detecting mutations in coding regions, but WES does not 
interrogate noncoding regions of the genome, and is not able to detect structural variants, or noncoding 
copy number variants. The comprehensive nature of WGS enables analysis of evolution and clonality 
at higher resolution. WGS and WES combined may provide the optimal window on the breadth, 
depth, and allelic fraction of somatic events. However, where limitations in tissue or resources 
mandate a choice of one or the other, the decision will depend on the purpose of the (sub) project. 
GLASS franchises with a focus on clinical relevance may lean toward WES, while projects aiming to 
define clonal relationships may opt to perform WGS. 
Targeted sequencing data in absence of a matching germline sample is frequently performed 
in the clinical setting and such datasets, which are typically able to provide mutation calls on 20–400 
genes, may therefore be easily accessible. While GLASS does not intend to pursue generating such 
datasets, aggregating information from existing resources may be a viable option to learn or validate 
mutations enriched at diagnosis or recurrence. 
 
4.2 Clinical annotation in GLASS 
Aggregating clinical annotation across the Consortium will help enable linkage of genotype with 
clinical and morphological phenotype in primary and recurrent settings. The number of clinical 
annotation elements will be different in each country with minimal requirements (Box 1). The GLASS 
clinical annotation committee will standardize clinical and imaging data collection for prospective 
studies and oversee collection of the clinical and imaging data from patients whose profiles are already 
included in the composite dataset. Each individual franchise will make data accessible in a 
comprehensible way by integrating clinical, imaging, and molecular parameters to explore correlation 
with relapse data. Currently, radiology and imaging are part of the clinical annotation committee. By 
mapping imaging features in a voxel-wise manner and correlating these spatially with molecular 
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alterations obtained from different parts of the tumor we aim to assess the entire tumor and to 
determine intratumoral heterogeneity. 
4.3 Data infrastructure  
A designated committee will maintain standardized data processing, data management and data 
sharing. A characteristic of the GLASS consortium is that data will be generated at multiple 
institutions distributed over multiple countries. As the regulations pertaining to ethical use of 
sequencing datasets are continuously evolving, GLASS will follow the example set by ICGC to 
perform decentralized data analysis to avoid cross-border exchange of patient-sensitive raw 
sequencing data. Batch effects may arise from varying library preparations, analyzing fresh frozen vs 
FFPE tissue, sequencing platforms, laboratories, etc.  Batch effects are most perturbing when 
performing unsupervised analysis, such as unsupervised clustering from expression or DNA 
methylation profiles. Adequately correcting for these items will be necessary to obtain usable data.  
The GLASS data infrastructure committee has developed Docker software images that are 
shared among participating institutions and that enable analysis uniformity. Like a shipping container, 
a Docker image packages one or more software tools to establish a workflow resembling an 
executable application. Comparable to platform-independent Java software, the ready-to-run Docker 
images are independent of the local computational environment. Along the same lines, comparable 
Singularity images have been prepared. The GLASS participants run these images locally, which 
initializes a per-sample-per-analysis Docker/Singularity container, resulting in data analysis using an 
identical software environment and run parameters. Docker/Singularity images and documentation are 
available for download through http://docker.glass-consortium.org 
The data infrastructure committee will also coordinate mechanisms for dissemination of 
results, as to widely share datasets with the community. We may explore mechanisms such as 
the Genomic Data Commons, or similar, to align our efforts with other molecular profiling 
studies. 
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5. Final remarks and perspectives 
Survival and quality of life for patients with diffuse gliomas remains dismal with standard 
treatments. Diffuse glioma is a fatal disease with an enormous societal burden as a result of the short 
survival following high-grade disease and the young age at diagnosis of lower-grade disease. This not 
only affects patients in the prime of their life, but also puts enormous burden on their immediate 
entourage, as they need extensive supportive care and navigation through a complicated medical 
landscape, and experience difficulties with medical costs and insurance. While cures of diffuse 
gliomas remain elusive, our patients demand better therapies. With no substantive impact of molecular 
medicine to date, in practice treatments remain “one size fits all”. The GLASS Consortium aims to 
improve clinical outcomes by establishing a broadly useful dataset that will provide pivotal new 
insights into the mechanisms used by gliomas to defy therapeutic challenges. 
Importantly, GLASS is also an opportunity for the exchange of knowledge among an 
international group of collaborators to ultimately build smarter clinical trials and develop therapies 
that will extend survival and improve the quality of life of people with diffuse gliomas. GLASS is well 
positioned to demonstrate the value of well-coordinated collaborative efforts. To that end, new 
investigators are invited to join to the consortium, where the major criteria for participation are the 
ability to offer datasets of longitudinally profiled glioma patients or the availability of suitable tissue 
samples. 
In summary, through the GLASS Consortium, we aspire to continue the immeasurable success 
of TCGA, while increasing the focus on making a difference to patients and their families. 
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Figure Legends 
Figure 1. Usual course of glioma management. GLASS would improve the assessment of 
gliomas, particularly the prediction of malignant transformation, treatment monitoring, and 
assessment of tumor alterations non-invasively with imaging and/or liquid biopsies. SMDT 
(tumor board): Specialist multidisciplinary team; RT: Radiotherapy. 
Figure 2. Simplified glioma evolution models. The glioma initiating cell evolves into the tumor at 
diagnosis with selective pressures resulting in intratumoral heterogeneity. Recurrent tumors share 
between few or the majority of the somatic alterations seen in the diagnostic tumors depending on the 
evolutionary pattern (linear, branching, or ancestral evolutions). Subclones may be marked by 
mutations or extrachromosomal DNA elements. 
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Table 1. 
Table 1. Summary of cohort based longitudinal characterization of glioma studies. 
# Publication Journal PMID Year Data types Glioma type 
at diagnosis 
Cohort size 
(#patients) 
1. 
Phillips et 
al15 
Cancer 
Cell 
16530701 
Mar 
2006 
Gene 
expression 
arrays 
High grade 23 
2. 
Johnson et 
al36 
Science 24336570 
Dec 
2013 
Exome 
sequencing 
Low grade 23 
3. Kim et al34 
Genome 
Res 
25650244 
 Feb 
2015 
Whole genome 
and exome 
sequencing, 
DNA copy 
number arrays 
Glioblastoma 23¥1 
4. 
Suzuki et 
al17 
Nat 
Genetics 
25848751 
Apr 
2015 
Exome 
sequencing 
Low grade 10 
5. Kim et al68 
Cancer 
Cell 
26373279 
Sep 
2015 
Exome 
sequencing, 
array CGH, 
RNA 
sequencing 
Glioblastoma 38 
6. Mazor et al43 
Cancer 
Cell 
26373278 
Sep 
2015 
DNA 
methylation, 
RNA 
sequencing 
Low grade 21*1 
7. Kwon et al73 
PLoS 
One 
26466313 
Oct 
2015 
Gene 
expression 
arrays 
Glioblastoma 15 
8. Bai et al44 
Nat 
Genetics  
26618343 
Nov 
2015 
Exome 
sequencing, 
array CGH, 
gene 
expression 
arrays, DNA 
Low grade 41 
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methylation 
9. Wang et al69 
Nat 
Genetics 
27270107 
July 
2016 
Exome 
sequencing 
Glioblastoma 39*2 
10. 
DeCarvalho 
et al48 
Biorxiv NA 
Nov 
2016 
Whole genome 
sequencing and 
CGH arrays 
Glioblastoma 21¥2, *3 
11. Wang et al59 
Cancer 
Cell 
28697342 
June  
2017 
Gene 
expression 
arrays, RNA 
sequencing 
Glioblastoma 36¥3, *4 
12. 
Klughammer 
et al79 
Biorxiv NA 2017 
DNA 
methylation 
Glioblastoma 112 
13. 
Ferreira de 
Souze et al78 
Biorxiv NA 2017 
DNA 
methylation 
Low grade 32¥4,*4 
 
Footnotes 
*1 Additional characterization on cohort from #2 
*2 Analysis additionally includes data from cohorts in #2, #3, #4, #5   
*3 Analysis additionally includes data from cohorts in #3, #5  
*4 Additional characterization on cohort from #3, includes re-analysis of cohorts from #1, #6, 
#7 
*5 Analysis additionally includes data from cohorts in #6, #8 
¥1 Including 13 glioma pairs from TCGA 
¥2 Including 14 glioma pairs from TCGA 
¥3 Additional characterization on 27 glioma pairs from TCGA, overlapping with ¥1 and ¥2 
¥4 Including 27 glioma pairs from TCGA, overlapping with ¥1 and ¥2 
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Figure 1. 
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Figure 2. 
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